Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pretreatment selection of regimen according to genetic analysis improves the efficacy of chemotherapy in the first line treatment of metastatic colorectal cancer.

Journal of surgical oncology - 1 Mar 2014

Kim Do Yoon, Paek Tae Yoon, Oh Seung Yeop, Kim Young Bae, Lee Je Hee, Lee Mi Young, Choi Zi Sun, Suh Kwang Wook

Abstract excerpt

BACKGROUND AND OBJECTIVES: Metastatic colon cancer patients are treated with the chemotherapy regimens, FOLFOX and FOLFIRI, in either order. So far, we cannot predict the response of chemotherapeutic agent, so it is necessary to find which regimen is adequate before starting chemotherapy. METHODS: Enrolled patients are randomized into either conventional treatment or planned treatment preceded by pretreatment...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Camptothecin
Share to Fluorouracil

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Glucuronosyltransferase

Share to Glutathione S-Transferase pi

Share to Leucovorin

Share to Organoplatinum Compounds

Share to X-ray Repair Cross Complementing Protein 1

Share to Xeroderma Pigmentosum Group D Protein

Source

Identifiers

PMID: 24318863
DOI: 10.1002/jso.23500

Genes

XRCC1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pretreatment selection of regimen according to genetic analysis improves the efficacy of chemotherapy in the first line treatment of metastatic colorectal cancer.PMID 24318863Read ↗

Association of single nucleotide polymorphisms in MTHFR and ABCG2 with the different efficacy of first-line chemotherapy in metastatic colorectal cancer.Semantic proximity Read ↗

Correlation between UGT1A1 gene polymorphism and irinotecan chemotherapy in metastatic colorectal cancer：a study from Guangxi ZhuangSemantic proximity Read ↗

Correlation between UGT1A1 gene polymorphism and irinotecan chemotherapy in metastatic colorectal cancer: a study from Guangxi Zhuang.Semantic proximity Read ↗

FOLFOX/FOLFIRI pharmacogenetics: the call for a personalized approach in colorectal cancer therapy.Semantic proximity Read ↗

UGT1A1 polymorphism can predict hematologic toxicity in patients treated with irinotecan.Semantic proximity Read ↗

Determination of the UGT1A1 polymorphism as guidance for irinotecan dose escalation in metastatic colorectal cancer treated with first-line bevacizumab and FOLFIRI (PURE FIST).Semantic proximity Read ↗

Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.Semantic proximity Read ↗

Regimen selection for first-line FOLFIRI and FOLFOX based on UGT1A1 genotype and physical background is feasible in Japanese patients with advanced colorectal cancer.Semantic proximity Read ↗

Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFIRI chemotherapy.Semantic proximity Read ↗

Multiple genetic polymorphisms in the prediction of clinical outcome of metastatic colorectal cancer patients treated with first-line FOLFOX-4 chemotherapySemantic proximity Read ↗

Oxaliplatin, irinotecan and capecitabine as first-line therapy in metastatic colorectal cancer (mCRC): a dose-finding study and pharmacogenomic analysis.Semantic proximity Read ↗

Prognostic advantage of irinotecan dose escalation according to uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) genotyping in patients with metastatic colorectal cancer treated with bevacizumab combined with 5-fluorouracil/leucovorin with irinotecan in a first-line setting.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.